Frequency Distribution of Dextromethorphan O-Demethylation ‎in a Greek Population

7413's picture
Journal Title, Volume, Page: 
Int J Clin Pharmacol Ther. 43(3):150-3.
Year of Publication: 
2005
Authors: 
Kanaze, F I
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Current Affiliation: 
Department of Pharmacy,Faculty of Medicine & Health Sciences, An-Najah National University, Nablus, Palestine
Kimiskidis, V K
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Niopas, I
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Firinidis, P D
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Gabrieli, C
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Kazis, D
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Papagiannopoulos, S
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Kazis, A
Department of Neurology, George Papanicolaou Hospital, Aristotle University, Thessaloniki, Greece
Preferred Abstract (Original): 
Objective
To determine the CYP2D6 phenotype in a Greek population by using dextromethorphan (DM) as a probe drug.
Methods
DM (30 mg) was given orally to 102 unrelated Greek subjects and 8-hour urine samples were collected. Concentrations of DM and its metabolite dextrorphan (DX) were determined using a validated HPLC assay. Metabolic molar ratio (MR) of DM to free DX in log form was used as an in vivo index of metabolic status.
Results
The frequency distribution histogram of MR was bimodal. An antimode of 0.25 for the mean log MR was determined using probit analysis. Seven of 102 subjects (6.9%) were poor metabolizers (PMs).
Conclusion
The PM frequency of CYP2D6 in Greek subjects was similar to other Caucasian populations.